Methyl Ethers

• 

  Subject Areas on Research

  • (3H)norepinephrine binding: unrelated to catechol-O-methyl transferase. 
  • A Randomized Controlled Trial to Determine the Effect of Depth of Anesthesia on Emergence Agitation in Children. 
  • Absence of biochemical evidence for renal and hepatic dysfunction after 8 hours of 1.25 minimum alveolar concentration sevoflurane anesthesia in volunteers. 
  • Acute and Long-Term Effects of Brief Sevoflurane Anesthesia During the Early Postnatal Period in Rats. 
  • An evaluation of remifentanil-sevoflurane response surface models in patients emerging from anesthesia: model improvement using effect-site sevoflurane concentrations. 
  • Anti-inflammatory signaling during ex vivo liver perfusion improves the preservation of pig liver grafts before transplantation. 
  • Assessment of low-flow sevoflurane and isoflurane effects on renal function using sensitive markers of tubular toxicity. 
  • Avoiding Cardiovascular Collapse: Pediatric Cutaneous Mastocytosis and Anesthetic Challenges. 
  • Biotransformation of L-cysteine S-conjugates and N-acetyl-L-cysteine S-conjugates of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A) in human kidney in vitro: interindividual variability in N-acetylation, N-deacetylation, and beta-lyase-catalyzed metabolism. 
  • Biotransformation of sevoflurane. 
  • Biotreatment of groundwater contaminated with MTBE: interaction of common environmental co-contaminants. 
  • Cardiac arrhythmias following anesthesia induction in infantile-onset Pompe disease: a case series. 
  • Clinical sevoflurane metabolism and disposition. I. Sevoflurane and metabolite pharmacokinetics. 
  • Clinical sevoflurane metabolism and disposition. II. The role of cytochrome P450 2E1 in fluoride and hexafluoroisopropanol formation. 
  • Comparison of Amsorb, sodalime, and Baralyme degradation of volatile anesthetics and formation of carbon monoxide and compound a in swine in vivo. 
  • Comparison of renal function following anesthesia with low-flow sevoflurane and isoflurane. 
  • Compound A uptake and metabolism to mercapturic acids and 3,3,3-trifluoro-2-fluoromethoxypropanoic acid during low-flow sevoflurane anesthesia: biomarkers for exposure, risk assessment, and interspecies comparison. 
  • Cytotoxicity of S-conjugates of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl) vinyl ether (Compound A) in a human proximal tubular cell line. 
  • Effect of sevoflurane on P50 and on measurement of oxygen tension. 
  • Evidence for metabolism of fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A), a sevoflurane degradation product, by cysteine conjugate beta-lyase. 
  • Gene expression profiling of nephrotoxicity from the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether ("compound A") in rats. 
  • Getting oil and water to mix. 
  • Glutathione S-conjugation of the sevoflurane degradation product, fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A) in human liver, kidney, and blood in vitro. 
  • Heart rate variability dynamics during controlled hypotension with nicardipine, remifentanil and dexmedetomidine. 
  • Human kidney methoxyflurane and sevoflurane metabolism. Intrarenal fluoride production as a possible mechanism of methoxyflurane nephrotoxicity. 
  • Hyperbaric oxygen therapy and neurological disease. 
  • Identification in rat bile of glutathione conjugates of fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl ether, a nephrotoxic degradate of the anesthetic agent sevoflurane. 
  • Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane. 
  • Long-duration low-flow sevoflurane and isoflurane effects on postoperative renal and hepatic function. 
  • Long-term human pluripotent stem cell self-renewal on synthetic polymer surfaces. 
  • Low-flow sevoflurane compared with low-flow isoflurane anesthesia in patients with stable renal insufficiency. 
  • Metabolism and toxicity of the new anesthetic agents. 
  • Methyl tert-butyl ether (MTBE) degradation by a microbial consortium. 
  • Modified extraction procedure for gas-liquid chromatography applied to the identification of anaerobic bacteria. 
  • Myocardial ischemia and adverse cardiac outcomes in cardiac patients undergoing noncardiac surgery with sevoflurane and isoflurane. Sevoflurane Ischemia Study Group. 
  • Nephrotoxicity of sevoflurane compound A [fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether] in rats: evidence for glutathione and cysteine conjugate formation and the role of renal cysteine conjugate beta-lyase. 
  • Odor and volatile organic compound removal from wastewater treatment plant headworks ventilation air using a biofilter. 
  • Opioid-volatile anesthetic synergy: a response surface model with remifentanil and sevoflurane as prototypes. 
  • P450-dependent and nonenzymatic human liver microsomal defluorination of fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A), a sevoflurane degradation product. 
  • Pharmacovigilance and safety aspects of sevoflurane. 
  • Response to 'Correlation between bispectral index and age-adjusted minimal alveolar concentration' (Br J Anaesth 2020; 124:e8). 
  • Role of cytochrome P4503A in cysteine S-conjugates sulfoxidation and the nephrotoxicity of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A) in rats. 
  • Role of renal cysteine conjugate beta-lyase in the mechanism of compound A nephrotoxicity in rats. 
  • Safety of low-flow sevoflurane anesthesia in patients with chronically impaired renal function is not proven. 
  • Sevoflurane Induces Coherent Slow-Delta Oscillations in Rats. 
  • Sevoflurane and halothane reduce focal ischemic brain damage in the rat. Possible influence on thermoregulation. 
  • Sevoflurane formulation water content influences degradation by Lewis acids in vaporizers. 
  • Sevoflurane, fluoride ion, and renal toxicity. 
  • Source proximity and outdoor-residential VOC concentrations: results from the RIOPA study. 
  • Spectrum and subcellular determinants of fluorinated anesthetic-mediated proximal tubular injury. 
  • Speed of recovery and side-effect profile of sevoflurane sedation compared with midazolam. 
  • Sulfoxidation of cysteine and mercapturic acid conjugates of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A). 
  • The effect of isoflurane on neuronal necrosis following near-complete forebrain ischemia in the rat. 
  • The hemodynamic and renal effects of sevoflurane and isoflurane in patients with coronary artery disease and chronic hypertension. Sevoflurane Ischemia Study Group. 
  • Time-varying spectral analysis revealing differential effects of sevoflurane anaesthesia: non-rhythmic-to-rhythmic ratio. 
  • Toxicity of methyl-tert-butyl ether to freshwater organisms. 
  • When is a bispectral index of 60 too low?: Rational processed electroencephalographic targets are dependent on the sedative-opioid ratio. 
  • Xenon and sevoflurane provide analgesia during labor and fetal brain protection in a perinatal rat model of hypoxia-ischemia. 
  • [Compound A: toxicology and clinical relevance].